Display Settings:

Format

Send to:

Choose Destination

    Transplantation. 2005 Dec 15;80(11):1541-5.

    Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism.

    Powell JD, Fitzhugh C, Kang EM, Hsieh M, Schwartz RH, Tisdale JF.

    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

    BACKGROUND: The ability to achieve significant donor engraftment without fully myeloablative conditioning has revolutionized allogeneic stem cell transplantation. These nonmyeloablative approaches may allow extension of this potentially curative modality to an increasing number of patients including those with non-malignant diseases. Although a number of regimens have been explored, the optimal means of conditioning has not been determined. METHODS: We previously demonstrated that rapamycin (RAPA) has the ability to promote T-cell tolerance even in the presence of costimulation. In the current study, we examine the ability of rapamycin or the calcineurin inhibitor cyclosporine A (CSA) to promote chimerism in a murine haploidentical bone marrow transplantation model. Mice were conditioned with 300 cGy and received either RAPA at 3 mg/kg/day IP, CSA at 20 mg/kg/day IP, or no immunosuppression starting on the day before the transplant and continued for 4 weeks. RESULTS: There was no apparent toxicity, and animals maintained normal blood counts throughout. More importantly, long-term macrochimerism was observed only in the RAPA-treated group. CONCLUSIONS: These results establish a simple, nontoxic, irradiation-based regimen that facilitates engraftment without ablation. This strategy may prove useful in nonmalignant disorders such as hemoglobinopathies in which moderate levels of donor chimerism could prove curative.

    PMID: 16371922 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information

    • Cyclosporine (Neoral®, Sandimmune®, Gengraf®)

      Cyclosporine and cyclosporine (modified) are used with other medications to prevent transplant rejection (attack of the transplanted organ by the immune system of the person who received the organ) in people who have rec...

    • Sirolimus (Rapamune®)

      Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppressants. It works by suppressing the body's immune system.